Effect of Telmisartan Versus Captopril on Insulin Resistance in Hypertensive Type 2 Diabetic Patients | ||
| Mosul Journal of Nursing (Print ISSN: 2311-8784 Online ISSN: 2663-0311) | ||
| Article 8, Volume 2, Issue 2, August 2014, Pages 99-106 PDF (609.44 K) | ||
| Document Type: Original Articles | ||
| DOI: 10.33899/mjn.2014.162935 | ||
| Authors | ||
| Adnan Ali Zainal; Fadhel Abbas Al-Hamamy | ||
| Abstract | ||
| Background and objectives: Hypertension is an extremely common co-morbid condition in diabetes. Peripheral insulin resistance (IR) plus compensatory hyperinsulinaemia is a common mechanism underlying both hypertension and diabetes. The aim of this study was to compare the effects of telmisartan and captopril on IR in type2 diabetes mellitus with hypertension. Materials and Methods: This study was conducted in the Department of Pharmacology, Mosul College of Medicine, University of Mosul and Al-Wafaa center for diabetes management, Mosul, Iraq, from 1 March, 2012 to 30 March, 2013. Sixty-eight patients on oral hypoglycemic agents were assigned to receive two month treatment of either telmisartan (n = 34) or captopril (n = 34). Forty diabetic normotensive patients, with age and BMI, matched to the diabetic hypertensive patients, served as a control group. The oral hypoglycemic agents remained unchanged during the two- months study period. Insulin resistance was estimated by homeostasis model assessment of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI). Results: This study showed that the two groups of diabetic hypertensive patients who were assigned to receive captopril or telmisartan have a non-significant difference in fasting serum glucose (FSG), fasting serum insulin (FSI), QUICKI and HOMA- IR before starting therapy. Telmisartan and captopril groups showed insignificant change in body mass index (BMI). HOMA-IR, QUICKI, FSI and FSG were changed non-significantly in telmisartan group; while FSI, FSG and HOMA-IR decreased significantly (from 18.1± 9.69 to 15.14 ± 7.49, p=0.022; and from 187.32± 65.34 to 162.95 ± 56.87, p=0.048; and from 8.27 ± 6.28 to 6.02 ± 3.73, p-value= 0.027, respectively) and QUICKI increased significantly (from 0.293 ± 0.024 to 0.306 ± 0.031, p-value = 0.022) in the captopril group versus baseline. Conclusion: Captopril, but not telmisartan, significantly improves insulin sensitivity in diabetic hypertensive patients. Keywords: Captopril, HOMA-IR, telmisartan, type 2 diabetes. | ||
| Keywords | ||
| Captopril; HOMA-IR; telmisartan; type 2 diabetes | ||
| References | ||
|
Alkharouf, J.; Nalinikumari, K.; Cony, D. and Tuck, M.(1993). Long-term effects of angiotensin converting enzyme inhibitor captopril on metabolic control in non-insulin-dependent diabetes mellitus. Am J Hypertens. 6. P.p. 337-343.
Bahadir, O.; Uzunlulu, M.; Oguz, A. and Bahadir, M.A. (2007). Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res. 30. P.p. 49-53.
Benson, S.C.; Pershadsingh, H.A.; Ho, C.I.; Chittiboyina, A.; Desai, P.; Pravenec M.; Qi, N.; Wang, J.; Avery, M.A. and Kurtz, T.W. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ–modulating activity. Hypertension. 43. P.p. 993-1002.
Berra, K. and Miller, N.H. (2009). Inhibiting the renin–angiotensin system: Why and in which patients. J Am Acad Nurse Pract. 21. P.p. 66–75.
Cohen, D.L. and Townsend, R.R. (2008, Oct. 10). What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker? J Cl Hypertens. 10(10). P.p. 803-804.
Derosa, G.; Cicero, A.F.G.; Ciccarelli, L. and Fogari, R. (2003). A randomized, double-blind, controlled parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 25. P.p. 2006-2021.
Derosa, G.; Cicero, A.F.G.; Bertone, G.; Piccinni, M.N.; Fogari, E.; Ciccarelli, L.; and Fogari, R. (2004a). Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther. 26 (8). P.p. 1228–1236.
Derosa, G.; Ragonesi, P.D.; Mugellini, A.; Ciccarelli, L.; and Fogari, R. (2004b). Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 27 (7). P.p. 457-464.
Derosa, G.; Fogari, E.; D’Angelo, A.; Cicero, A.F.G.; Salvadeo, S.A.T.; Ragonesi, P.D.; Ferrari, I.; Gravina, A.; Fassi, R. and Fogari, R. (2007). Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther. 32. P.p. 261–268.
Esteghamati, A.; Ashraf, H.; Khalilzadeh, O.; Zandieh, A.; Nakhjavani, M.; Rashidi, A.; Haghazali, M. and Asgari, F. (2010). Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab. 7. P.p. 26. 1-8.
Giordano, M.; Matsuda, M.; Sanders, L.; Canessa, M.L.; and DeFronzo, R.A. (1995). Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 44. P.p. 665-671.
Gordon, L.; Ragoobirsingh, D.; Morrison, E.; McGrowder, D.; Choo-Kang, E. and Martorell, E. (2010, Oct). Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica. Arch Med Sci. 6(5). p.p. 701–708.
Huang, G.Z.; Tang, Y.H.; Wang, B.Y.; Zhang, B.; Hu, T.J.; Zhang, L.; Zhang, X.Y. and Zhong, Y. (2011). Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J. 32 (10). P.p. 1017-1021.
Ibrahim, I.A.; Al-Joudi, F.S.; Suleiman, R.W. and Al-Saffar, B.H. (2010, Apr). Captopril interferes with some serum biochemical findings. Afr J Biochem Res. 4(4). P.p. 95-98.
Kurtz, T.W. and Pravenec, M. (2004). Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system. J Hypertens. 22 (12). P.p. 2253–2261.
Lotta, J.A. and Turner, K. (1975). Evaluation of trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem. 2. P.p. 1754-1760.
Mansour, A.A. (2012). Prevalence and control of hypertension in Iraqi diabetic patients: A prospective cohort study . Open Cardiovasc Med J. 6. P.p. 68-71.
Matheus, A.S.M.; Tannus, L.R.M.; Cobas, R.A.; Palma, C.C.S.; Negrato, C.A. and Gomes, M.B. (2013). Impact of Diabetes on Cardiovascular Disease: An Update. Int J Hypertens. 2013. P.p. 1-15.
McAuley, K.A.; Williams, S.M.; Mann, J.I.; Walker, R.J.; Lewis –Barned, N.J.; Temple, L.A. and Duncan, A.W. (2001). Diagnosis insulin resistance in the general population. Diabetes Care. 24. p.p. 460-464.
McFarlane, S.I.; Banerji, M. and Sowers, J.R. (2001). Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 86(2). p.p. 713-718.
Miura, Y.; Yamamoto, N.; Tsunekawa, S.; Taguchi, S.; Eguchi, Y.; Ozaki, N. and Oiso, Y. (2005). Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences. Diabetes Care. 28 (3). P.p. 757–758.
Muniyappa, R.; Lee, S.; Chen, H. and Quon, M.J. (2008). Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 294. P.p. E15–E26.
Odegaard, A.; Koh, W.P.; Vazquez, G.; Arakawa, K.; Lee, H.P.; Yu, M. and Pereira, M. (2009, Jun). BMI and Diabetes Risk in Singaporean Chinese. Diabetes Care. 32(6). p.p. 1104-1106.
Olivares-Reyes, A.; Arellano–Plancarte, A. and Castillo-Hernandez, J.R. (2009). Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol. 302. P.p. 128–139.
Östergren, J. (2007, May). Renin–angiotensin-system blockade in the prevention of diabetes. Diab Res Clin Prac. 76(3). P.p. S13-S21.
Otero, M.L. (2007). Manidipine–delapril combination in the management of hypertension. Vasc Health Risk Manag. 3(3). P.p. 255–263.
Patel, B.M. and Mehta, A.A. (2012). Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol. 697. P.p. 1–12.
Patel, B.M and Mehta, A.A. (2013, Sep). Choice of anti-hypertensive agents in diabetic subjects. Diab Vasc Dis Res. 10(5). P.p. 385-396.
Prasad, A. and Quyyumi, A.A. (2004). Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome. Circulation. 110. P.p. 1507-1512.
Rett, K.; Wicklmayr, M.; Tschollar, W.; Dietze, G. and Mehnert, H. (1988). Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in non-insulin dependent diabetes mellitus. Postgrad Med J. 64 .Suppl 3. P.p. 69-74.[Abstract].
Romero, R.; Salinas, I.; Teixidó, J.; Lucas, A.; Felip, A. and Sanmarti, A. (1990, Dec). Long term follow-up of the effect of captopril on severe proteinuria in hypertensive diabetic patients. J Hum Hypertens. 4(6). P.p. 671-675.
Romero, R.; Salinas, I.; Lucas, A.; Teixidó, J.; Audi, L. and Sanmarti, A. (1992, Sep). Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diab Res Clin Pract. 17(3). P.p. 191–198.
Saini, V. (2010, Jul.).Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes. 1(3). P.p. 68-75.
Savage, D.B.; Petersen, K.F. and Schulman, G.I. (2005). Mechanisms of insulin resistance in humans and possible Links with inflammation. Hypertension. 45. p.p. 828-833.
Savage, D.B.; Petersen, K.F. and Schulman, G.I (2007). Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance. Physiol Rev. 87. P.p. 507–520.
Schutta, M.H. (2007). Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions. J Cardiometab Syndr. 2(2). P.p. 124-30.
Singh, B. and Saxena, A. (2010).Surrogate markers of insulin resistance: A review. World J Diabetes. 1(2). P.p. 36-47.
Standl, E.; Erbach, M. and Schnell, O. (2012). What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. Diabetes Metab Res Rev. 28 (Suppl. 2). P.p. 60–66.
Steven, E.; Rebecca, L. and Kristina, M. (2006). Review Article Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444. P.p. 840-846.
Tillmann, H.C.; Walker, R.J.; Lewis-Barned, N.J.; Edwards, E.A. and Robertson, M.C. (1997, Aug). A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. J Clin Pharm Ther. 22(4). p.p. 273-278.
Torlone, E.; Britta, M.; Rambotti, A.M.; Perriello, G.; Santeusanio, F.; Brunetti, P. and Bolli, G.B. (1993). Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care. 16. P.p. 1347-1355.
Taylor, A.A.; Siragy, H. and Nesbitt, S. (2011). Angiotensin receptor blockers: Pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich). 13(9). P.p. 677–686.
Vitale, C.; Mercuro, G.; Castiglioni, C.; Cornoldi, A.; Tulli, A.; Fini, M.; Volterrani, M. and Rosano, G.M.C. (2005). Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 4. P.p. 6-10.
Wohl, P.; Krusinova, E.; Hill, M.; Kratochvılova, S.; Zıdkova, K.; Kopecky, J.; Neskudla, T.; Pravenec, M.; Klementova, M.; Vrbıkova, J.; Wohl, P.; Mlejnek, P. and Pelikanova, T. (2010). Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur J Endocrinol. 163(4). P.p. 573-583.
Yamada, S.; Ano, N.; Toda, K.; Kitaoka, A.; Shiono, K.; Inoue, G.; Atsuda, K.; and Irie, J. (2008). Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res. 31. P.p. 601-606.
Yin, W.; Seghieri, G.; Boni, C.; Sanna, G.; Anichini, R.; Bartolomei, G. and Ferrannini, E. (1994, Mar). Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Chin Med Sci J. 9 (1). P.p. 29-33. | ||
|
Statistics Article View: 393 PDF Download: 443 |
||